61220-69-7

Tiopinac (0.03-110 mg/kg) has 40 times the antiphlogistic potency of phenylbutazone. The dose required to reduce paw swelling by 30% is approximately 0.5 mg/kg. Tiopinac does not elicit overt side effects at the 20 mg/kg/day dose. Tiopinac causes a dose-related reversal of the decreases body weight caused by the adjuvant disease, the weight of those rats receiving 0.135 and 0.4 mg/kg/day being significantly greater than that of the positive controls. Tiopinac (0.3-30 mg/kg) is highly potent in inhibiting the pain evoked in the yeastinflamed hind paw of the rat^[1].